|
山中伸彌博士,2017年,日本諾貝爾獎得主山2017年1月23日日本諾貝爾獎得主山中伸彌博士公開向世人道歉。
王玉祥,2000年,造血幹細胞移植的演進。台灣醫學,4(2)。
江偉芬,2013年,新藥開發技術之日韓前瞻趨勢分析,科技產業資訊室-江偉芬撰稿, 2013年10月1日。
自由經濟日報,2017年,前美國FDA官員陳紹琛(曾是華人圈在美國FDA職務最高官員)所說:台灣生醫界最大的問題就是落後的法規環境。
邱淳芬,2015年,幹細胞新藥產業創新經營成功因素之研究。為出版之碩士論文,私立中華大學企業管理研究所,新竹市。
周中林,2007年,台灣幹細胞產業經營策略之研究-以個案公司為例。未出版之碩士論文,國立台北大學國際財務金融碩士在職專班,新北市。
國璽網頁,2016年,幹細胞新藥GXHPC1-清肝淨,取自http://www.gwoxi.com.tw/index.php/frontend/tmp_cell_drug/view?tmp_cell_drug_id=5
張明富,2003年,後基因體時代之生物技術,教育部顧問室「生物技術科技教育改進計畫」。
張品俞,2011年,再生醫學及組織重組工程的前景與方向。取自http://www.ibmi.org.tw/client/ReportDetail.php?REFDOCTYPID =0kv7fkfs6uh20qiu&REFDOCID=0lnhtssxxtp17eln。
經濟部工業局,2013年,台灣生技產業的範圍2015生技產業白皮書。
楊玉齡(譯),潘震澤(審閱),Ann B. Parson(原著),2006年,海神效應,張老師文化。
鄭信德,2014年,臺灣生技產業效益之分析。臺灣銀行季刊,60(3),71-95。
劉岱良(主編),2008 年,喚醒生命力—幹細胞研究與再生醫學。新新聞文化出版,台北縣汐止市。
劉尚志,2001 年,智慧財產權與產業競爭-產業競爭、科寄發展與法律規範之策略思維。競爭政策通訊,5(5),1-10。
鄧哲明,2013年,新藥的研發流程概論。科學月刊,2013年8月13日,取自http://scimonth.blogspot.tw/2013/03/blog-post_6173.html
錄克雷頓.克里斯汀生,2016年,Clay M. Christensen對「破壞式創新」最具開創性的重大見解。
Aaker, D. A.(1989). ‘ManagingAssets and Skills: The Key to Sustainable Competitive. Advantage’. California Management Review, 31(2): 91–106.
Arojarvi, O.(2001). ‘How to value a biotechnology firms: A study of Current Approaches and Key Value Driver’. Helsinki School of Economics and Business Administration.
Baker, Monya, (2007). ‘Adult cells reprogrammed to pluripotency, without tumors’. Nature Reports Stem Cells.
B.Frederick(2003), Managing Technological Innovation Company, pp.40-45. 7.
Bruestle(2002), The importation and use of embryonic stem cells are prohibited.
Barney, J.B.(1986). ‘Strategic Factor Markets: Expectations, Luck and Business Strategy’. Management Science, 32(10) : 1231–1241.
Barney, J.B. (1986). ‘Organizational Culture: Can It be a Source of Sustained Competitive Advantage?’ Academy of Management Review,11(3) : 656–665.
Fishman, M. C., & Porter, J. A.(2005). ‘Pharmaceuticals: A new grammar for drug discovery’. Nature, 437, 491−493.
Hofer & Schendel.(1978). “Strategy formulation: Analytical concepts” the field's first textbook.
IMS. (2012). The Global Use of Medicines: Outlook Through 2016. IMS Institute for Healthcare Informatics.
J Niosi, TG Bas. (2001).”Small Business Economics.” 17 (1-2), 31-42
John R. Gurdon ,2012 ,The 2012 Nobel Prize for Medicine has been awarded to Drs. John B. Gurdon and Shinya Yamanaka for their creative discoveries in nuclear reprogramming
Lund Stem Cell Center(2003). Sweetland setup January.
Mason C. and Dunnill P.(2008). ‘A brief definition of regenerative medicine’. Regenerative Medicine, 3(1), 1-5
Mansfield, E., and S. Wagner. “Organizational and Strategic Factors(1975). Associated with Probabilities of Success in Industrial R&D.” Journal of Business 48, no. 2:179-198
M. L. Tushman, Lori Rosenkopf.(1992). ’Organizational determinants of technological-change-toward a sociology of technological evolution’. Research in organizational behavior, 14 : 311-347.
Murdick, R. G., Eckhouse, R. H., Moor, R.C., & Zimmerer, T.W. (1980).”Business policy : A framework for analysis (3rd ed.), Colimbus, OH: Grid Publishing
Patrick Sullivan. (1996).“Focus Groups Confirm that MDs, Public Differ on Role of Private Health Care.” Canadian Medical Association Journal 154.
Perez, Carlota.(2001). "Technological change and opportunities for development as a moving target." CEPAL Review75: 109-129.
Poter, M. E.(1980). ‘Competitive Strategy : Techniques for Analyzing Industries and Competitor’. New York : The Free Press.
Porter, M.E..(1990). ‘The Competitive Advantage of Nations’. New York: Free Press, MacMillan.
Takeuchi, Hirotaka and Nonaka, Ikujiro. (1986). ‘The new new product development game’. Harvard. Business Review 64:1:137-146.
Teece, David J.(1996). ‘Firm organization, industrial structure, and technological innovation’. Journal of Economic Behavior & Organization, 31(2) : 193-224.
Till, J.E. & McCulloch, E.A.(1961). ‘A direct measurement of the radiation sensitivity of normal mouse bone marrow cells’. Radiation Res,14 : 213-222
Wernerfelt, B.(1984). ‘The Resource-Based View of the Firm’. Strategic Management Journal, 5(2), 171–180.
World Preview 2015, Outlook To 2020, Evaluate Pharm, 2015 Global biotech market size. |